Galapagos enters into discovery collaboration with Idenix for infectious disease programs

25-Nov-2005

Galapagos NV announced that it has entered into a collaboration with Idenix Pharmaceuticals, Inc. on selected hepatitis and HIV infectious disease programs. Pursuant to the collaboration, Galapagos' service division BioFocus will supply its proprietary SoftFocus® chemical compound collections to Idenix and provide expertise in the design and synthesis of biologically-directed compound collections. In addition, BioFocus will provide hit-to-lead and lead optimisation services. The entire discovery contract collaboration is worth up to $2.5 million over two years.

This arrangement represents Galapagos' first collaboration with Idenix. Under the terms of the agreement, Galapagos will receive undisclosed technology access fees for SoftFocus® collections, as well as a fee component for medicinal chemistry services plus success payments upon realization of certain objectives relating to the identification of pre-clinical candidates.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance